INFANT'S ADVIL (ibuprofen) by GSK is cyclooxygenase inhibitors [moa]. First approved in 1998.
Drug data last refreshed Yesterday
Infant's Advil is an oral ibuprofen suspension formulated for pediatric use, indicated for pain and fever management in infants and young children. It works as a cyclooxygenase inhibitor, reducing prostaglandin synthesis to provide anti-inflammatory, analgesic, and antipyretic effects. The product addresses a critical gap in pediatric pain management where dosing precision and taste palatability are essential.
Product approaching loss of exclusivity after 26+ years on market; expect declining brand team headcount and shift toward cost-containment and generic-to-brand competitive strategies.
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effect of Extracorporeal Radial Shock Wave Ibuprofen Phonophoresis on Subacromial Space in Patients With Impingement Syndrome.
A Comparative Bioavailability Study of Reformulated Ibuprofen 2% and 4% Oral Suspensions (Berlin Chemie AG) and Versus Ibuprofen (Nurofen®) 200 mg/5 ml Oral Suspension
Efficacy and Safety of S (+) - Ibuprofen in Osteoarthritis Pain
Efficacy and Safety of S (+) - Ibuprofen in the Treatment of Mechanical Low Back Pain
Postoperative Analgesic Effects of Ibuprofen Versus Ketorolac in Patients Undergoing in Orthopedic Surgery
Worked on INFANT'S ADVIL at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on Infant's Advil offers stability in a mature, well-established brand but limited growth trajectory as the product approaches loss of exclusivity. Career advancement will depend on defensive commercial strategies (brand loyalty, patient adherence programs) and organizational agility to transition to a generic/OTC environment rather than on blockbuster sales expansion.